Key result
MAO inhibitors linked to ~10% lower arrhythmia risk versus SSRIs in depression.
Why the study?
Patients with depression have an increased risk of cardiac arrhythmias that may involve catecholamine metabolism, prompting investigation into the relationship between MAO-A activity and arrhythmogenesis.
Does MAO-A inhibition reduce the risk of arrhythmias in patients with depression and in preclinical models of catecholamine stress?
Observational (n=11,533)
Does MAO-A inhibition reduce the risk of arrhythmias in patients with depression and in preclinical models of catecholamine stress?
MAO-A inhibition mitigates arrhythmogenesis by enhancing diastolic calcium reuptake, suggesting a potential novel target for antiarrhythmic therapy.
Answers are grounded in this paper and cite their sources.
Association between MAOIs and lower arrhythmia risk is hypothesis-generating; prospective trials needed before clinical consideration.
Background People with clinical depression exhibit increased risk for cardiac arrhythmias that could be related to differences in catecholamine metabolism. Emerging studies have implicated a pathophysiologic role for monoamine oxidase (MAO-A), which catalyzes catecholamine metabolism in the heart. MAO-A is the pharmacological target of some classes of anti-depressants. Here, we investigated the relationship between MAO-A activity and arrhythmogenesis. Methods & Results TriNetX database analysis of adult patients with depression (n=11,533) revealed that MAO inhibitor (MAOI) treatment is associated with significantly lower risk of arrhythmias compared with selective serotonin reuptake inhibitor (SSRI) treatment (16.7% vs 18.6%, p=0.0002). To determine a mechanistic link between MAO activity and arrhythmia, we utilized a genetically modified mouse model with cardiomyocyte-specific MAO-A deficiency (cMAO-A def ). Compared with wild-type (WT) mice, cMAO-A def mice had a significant reduction in the incidence (38.9% vs. 77.8%, p=0.0409) and duration (55.33 ± 26.21s vs.163.1 ± 56.38s, p=0.0360) of catecholamine stress-induced ventricular tachyarrhythmias (VT). Reduced VT risk and duration were associated with altered cardiomyocyte Ca 2+ handling in the cMAO-A def hearts, including a marked increase in Ca 2+ reuptake rate, decreased diastolic Ca 2+ levels, decreased SR Ca 2+ load and reduced Ca 2+ spark activity following catecholamine stimulation relative to WT. Further analysis of molecular mechanisms revealed that altered Ca 2+ handling in the cMAO-A def hearts was related to decreased catecholamine-induced phosphorylation of Ca 2+ /calmodulin-dependent kinase II (CaMKII) and ryanodine receptor 2 (RyR2), and increased phosphorylation of phospholamban (PLB). Conclusions These findings suggest that MAO-A inhibition in cardiomyocytes mitigates arrhythmogenesis via enhanced Ca 2+ reuptake that lowers diastolic Ca 2+ levels thereby diminishing arrhythmic triggers following catecholamine stimulation. Thus, cardiac MAO-A represents a potential target for antiarrhythmic therapy.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2022) conducted an observational in depression (n=11,533). MAO inhibitor (MAOI) vs. selective serotonin reuptake inhibitor (SSRI) was evaluated on risk of arrhythmias (p=0.0002). MAO inhibitor treatment in adult patients with depression was associated with a lower risk of arrhythmias compared with SSRI treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: